Target intelligence / Profile preview

Microtubule-associated protein 1B (MAP1B)

Target
MAP1B
Molecular classification
Other (Microtubule-associated protein), Cytoskeletal protein
01

Overview

Microtubule-associated protein 1B (MAP1B) is a critical cytoskeletal protein encoded by the MAP1B gene, predominantly expressed in the developing and adult nervous system[1][2][4][5][8]. It is a large polyprotein that undergoes proteolytic processing into heavy and light chains, both of which associate with microtubules. MAP1B facilitates microtubule assembly, stability, and cross-talk with the actin cytoskeleton, processes fundamental to neurogenesis, axonal guidance, elongation, and synaptic plasticity[1][2][4][6][8]. Recent research shows MAP1B also modulates mitochondrial localization in neurons, regulates membrane trafficking, and influences autophagy by interacting with other proteins such as syntaxin 17[3]. Loss or mutation of MAP1B results in significant neurodevelopmental defects, underlining its essential role in nerve cell architecture and signaling[1][4][6]. The protein is not currently an established drug target, and no therapies directly modulate MAP1B in clinical practice.

Other names
MAP1B heavy chainMAP1B light chain LC1MAP1 light chain LC1MAP-1BMAP5PPP1R102Protein phosphatase 1, regulatory subunit 102DFNA83FUTSCHPVNH9
02

Mechanism of action

Not applicable; no known drugs target MAP1B directly

03

Biological functions

Microtubule assemblyNeurogenesisRegulation of microtubule dynamicsAxonal growth and guidanceNeuronal differentiationSynaptic structure and physiologyRegulation of autophagyMaintenance of neuronal cytoskeletonMitochondrial localization and axonal transportCrosstalk between microtubules and actin cytoskeleton
04

Disease associations

Neurodevelopmental disorders (e.g., Periventricular Nodular Heterotopia 9)Hearing loss (e.g., Deafness, Autosomal Dominant 83)Implicated in synaptic dysfunction (general nervous system disorders)Other (no strong evidence for roles in cancer, inflammation, or cardiovascular disease)
05

Safety considerations

Not applicable; no drugs targeting MAP1B are in clinical use, so no drug-specific safety concerns identified
06

Interacting drugs

None known or established as of now
07

Biomarkers

None established as routine clinical biomarkers

Beyond the preview

Go deeper on Microtubule-associated protein 1B (MAP1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microtubule-associated protein 1B (MAP1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call